|
Roche committed to innovation and growth
|
06 September 2012 |
|
Roche and Lucerne Festival renew partnership and launch new project for young composers
|
23 August 2012 |
|
FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema
|
20 August 2012 |
|
The Phase III AVAglio study met its co-primary endpoint
|
13 August 2012 |
|
Roche reports second positive study of RoACTEMRA
|
29 July 2012 |
|
Roche to streamline research and development activities
|
26 June 2012 |
|
People with HER2-positive metastatic breast cancer lived longer with Roche's Perjeta
|
24 June 2012 |
|
Roche employees in 52 countries walk to raise funds to support vulnerable children worldwide
|
15 June 2012 |
|
FDA approves Perjeta (pertuzumab) for people with HER2-positive metastatic breast cancer
|
13 June 2012 |
|
Trastuzumab emtansine (T-DM1) reduced the risk of cancer worsening or death
|
03 June 2012 |
|
Roche will report new data on important progress for people with advanced cancers at ASCO 2012
|
20 May 2012 |
|
Roche reports positive study of RoACTEMRA given by subcutaneous injection
|
07 May 2012 |
|
Roche on track for full-year targets - good sales growth in first quarter
|
13 April 2012 |
|
Roche sends second letter to Illumina shareholders
|
04 April 2012 |
|
Roche disappointed by Illumina, Inc.'s Board of Directors' rejection
|
03 April 2012 |
|
Roche's Herceptin given by subcutaneous injection offers greater convenience and reduces costs
|
26 March 2012 |
|
Roche receives request for additional information from the Federal Trade Commission
|
14 March 2012 |
|
Roche Annual General Meeting 2012
|
06 March 2012 |
|
Positive One Year results From Phase 3 Study in Central Retinal Vein Occlusion of VEGF Trap-Eye
|
20 February 2012 |
|
FDA grants Roche's pertuzumab Priority Review for previously untreated HER2-positive metastatic breast cancer
|
13 February 2012 |